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Background: Diabetic foot ulcer (DFU) as the leading cause of lower limb amputation is one of the most
important complications of diabetes mellitus (DM). Patient and physician’s education plays a significant role in DFU
prevention. While effective treatment and formulation of prevention guidelines for DFU require a thorough
understanding of characteristics of DFU patients and their ulcers, there are reports that not only patients’ but also
physicians’ information about these characteristics is inadequate. So we conducted this study to investigate these
characteristics.
Methods: Necessary data was collected from medical archives of DFU patients admitted between 2002 and 2008
in two university hospitals.
Results: 873 patients were included. Mean age was 59.3 ± 11.2 years and most of the patients developed DFU in
5th and 6th decades of their life. 58.1% were men. 28.8% had family history of DM. Mean duration of DM was
172.2 months. Mean duration of DFU was 79.8 days. Only 14.4% of the patients had Hemoglobin A1C < 7%. 69.6%
of the patients had history of previous hospitalization due to DM complications. The most prevalent co-morbidities
were renal, cardiovascular and ophthalmic ones. Most patients had “ischemic DFU” and DFU in their “right” limb.
The most prevalent location of DFU was patients’ toes, with most of them being in the big toe. 28.2% of the
patients underwent lower-limb amputations. The amputation rate in the hospital where the “multidisciplinary
approach” has been used was lower (23.7% vs. 30.1%).
Conclusions: Number of patients with DFU is increasing. DFU is most likely to develop in middle-aged diabetic
patients with a long duration of DM and poor blood sugar control who have other co-morbidities of DM. Male
patients are at more risk. Recurrence of DFU is a major point of concern which underscores the importance of
patient education to prevent secondary ulcers. As a result, educating medical and nursing personnel, applying
screening and prevention guidelines, and allocating more resources are of great importance regarding treatment of
DFU patients. Application of the “multidisciplinary approach” can reduce the rate of amputations. Primary care
physicians might be furnished with the information presented in the present study.
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One of the most important and disabling complications
of diabetes mellitus (DM) is the diabetic foot ulcers
(DFU). Development of DFU is traditionally believed to
result from a combination of oxygen deficiency caused
by peripheral vascular disease, peripheral neuropathy,
minor foot traumas, foot deformities, and infection
[1-3]. DFU, with a lifetime development risk of 15% [4],
incidence of 1–4%, and prevalence of 5.3% to 10.5% [5,6]
in all diabetic patients, accounts for more than half of
the non-traumatic lower-extremity amputations in the
world [7-11]. Globally, one lower limb is lost every
30 seconds because of DFU [12]. The range of mortality
following diabetic foot amputation is 39–80% after
5 years, which is worse than the mortality rate for most
malignancies [5]. Approximately, 20% of hospital admis-
sions among diabetic patients are in consequence of foot
problems [13]. Furthermore, DFU is among the most
prevalent causes of hospitalization and morbidity [10,14]
and is responsible for more days of hospital stay than
any other chronic complication of DM [15,16].
According to estimation of the burden of DM based
on Disability-Adjusted Life Years (DALYS) by the Endo-
crinology and Metabolism Research Center of Tehran
University of Medical Sciences in Iran in 2001 [17],
nearly 15% of overall burden of DM was due to foot
neuropathy, DFU, and amputation. DFU lesions are sig-
nificant health and socioeconomic problem as they exert
adverse effects on patients’ quality of life and impose
heavy economic burden on the patient and the state due
to rising the need for rehabilitative and home care ser-
vices [18,19]. Given the DFU’s high prevalence, heavy
burden, and severe impact on patients’ life quality, it is
advisable that sufficient heed be paid to prevention of
this particular complication of DM. Furthermore, while
effective treatment and formulation of prevention guide-
lines require a thorough understanding of characteristics
of DFU patients and their ulcers, there are reports that
not only patients’ but also physicians’ information about
these characteristics is inadequate and even the process
leading to ulceration and amputation is still not well
understood by many healthcare professionals [20]. In-
deed, several authors have reported the relative infre-
quency of foot evaluation by primary care physicians
and surgeons; as in the primary care setting, only 23–
49% of persons with DM have their feet evaluated on a
yearly basis [21].
We conducted this descriptive study to investigate
the characteristics of diabetic foot patients and their
foot ulcers.
Methods
This descriptive, retrospective study was carried out by
including all patients admitted because of DFU betweenthe years 2002 and 2008 in two tertiary university hospi-
tals (Dr. Shariati Hospital and Imam Khomeini Hospital)
in Tehran, capital of Iran. Medical archives of the pa-
tients were utilized and necessary data was collected
using a predesigned data collection sheet. The informa-
tion was thereafter entered into SPSS software, version
15, for analysis. The data collected comprised information
on the patient’s age and sex, family history of DM, duration
of DM and DFU, method of DM control, history of lower-
limb amputation, history of previous hospitalizations, loca-
tion of the foot ulcer, type of the foot ulcer, side of the foot
ulcer (right or left limb), co-morbidities found during
admission, laboratory data, duration of hospitalization, and
the outcome.
We defined renal co-morbidity as presence of micro-
albuminuria, macro-albuminuria, or end-stage renal disease;
cardiovascular co-morbidity as presence of hypertension or
ischemic heart disease; ophthalmic co-morbidity as presence
of simple or proliferative diabetic retinopathy or cataract.We
considered sensorimotor neuropathy in case of paresthesia,
loss or reduction of vibration, pressure, temperature or
superficial pain sensation or two-point discrimination (pin
prick test), decreased sensation on screening with a mono-
filament (10-g), absence or reinforcement of Achilles ten-
don reflex or presence of deformities in the foot. We also
defined autonomic neuropathy as presence of unexplained
orthostatic hypotension, gastroparesis, dyspepsia, diabetic
diarrhea or constipation, neurogenic bladder, erectile dys-
function, vaginal or skin dryness.
The study was reviewed and approved by the Ethics
Committee of the Endocrinology and Metabolism Re-
search Center of Tehran University of Medical Sciences. It
conforms to the provisions of the Declaration of Helsinki.
Results
Medical archives of 873 patients were included. The num-
ber of the patients admitted in each year is illustrated in
Figure 1. The basic characteristic data of the patients is
shown in Table 1.
Only 4.18% of the patients had DM duration of
12 months or less. Mean duration of DFU prior to
admission was 79.8 days. A total of 384 (43.99%) patients
were under treatment with oral hypoglycemic agents,
397 (45.47%) were receiving insulin, 20 (2.29%) were re-
ceiving both oral hypoglycemic agents and insulin, and
72 (8.25%) were under no medication for blood sugar.
Mean Hemoglobin A1C (HbA1C) level was 9.51%, and
only 14.4% of the patients had HbA1C < 7%. Mean pa-
tients’ first fasting blood sugar during admission was
198.7 mg/dl. 69.6% of the patients had history of previous
hospitalization due to DM complications. The causes of
previous hospitalizations are shown in Table 2.
16.4% of the patients had previous lower-limb amputa-
tions, including major lower-limb amputation (above ankle)
Figure 1 Number of patients in each year. This figure shows that total number of diabetic foot patients who were admitted in the studied
hospitals during recent years is significantly more than that during the preceding years.
Madanchi et al. Journal of Diabetes & Metabolic Disorders 2013, 12:36 Page 3 of 6
http://www.jdmdonline.com/content/12/1/36in 4% and minor lower-limb amputation (below ankle) in
12.4% of the patients.
During hospitalization, patients were evaluated about
presence of DM co-morbidities. Data about presence of
DM co-morbidities in the patients is shown in Table 3.
74.1% of the patients had ischemic DFU, 17.4% had
neuropathic DFU, and 8.5% had neuro-ischemic DFU.
53.4% of the patients had DFU in the right lower limb,
38.8% in the left lower limb, and 7.8% in both lower limbs.
Locations of DFUs in our patients are summarized in
Table 4. The most prevalent location of DFU was pa-
tients’ toes, with most of them being in the big toe
followed by the second toe. Twenty-six patients had
DFU at the site of previous surgeries like amputation,
debridement, or venous graft removal for coronary ar-
tery bypass graft (CABG).
Eventually 28.2% of the patients had undergone lower-
limb amputations: 61.7% of the cases were minor ampu-
tations and 38.3% were major amputations.
Mean duration of hospitalization was 16.7 ± 11.3 days
(range = 1–87 days), and the mortality rate was 5.2%.Table 1 Basic demographic characteristics of the patients
Variable Result
Total number of patients 873
Male (%) 510 (58.1)
Female (%) 363 (41.9)
Mean age ± SD (year) 59.3 ± 11.2
Age (range in year) 25–87
Mean duration of DM ± SD (month) 172.2 ± 100.4
Duration of DM (range in month) 0–600
Positive family history of DM (%) 251 (28.8)Discussion
Globally, the total number of people with DM is ex-
pected to rise from 171 million in 2000 to 366 million in
2030 [22]. Consistent with global predictions, total num-
ber of people with DM in Iran and accordingly, the
number of patients with DFU are expected to increase.
Figure 1 demonstrates that the overall number of DFU
patients in our hospitals has risen in recent years. Simi-
larly, the number of DFU patients admitted in these two
hospitals had increased between the years 1979 and
2001 [23]. As a result, educating medical and nursing
personnel, applying screening and prevention guidelines,
and allocating more resources are of great importance in
treatment of DFU patients.
Most of our patients developed DFU in 5th and 6th
decades of their life, with the mean age being 59.3 years.
Other studies also have found the average age of devel-
oping DFU to be about 55–60 years [23-26]. Male pa-
tients accounted for 58.1% of our total study population.
Other investigators have also reported male patients to
comprise 50–63.3% of their study populations [23-26];Table 2 Causes of patients’ previous hospitalizations





Uncontrolled blood sugar 3
Cerebrovascular accident 2.8
Renal 2.4
Two or more of these complications 21.3
Table 3 Prevalence of DM co-morbidities in patients







Renal co-morbidity: Micro-albuminuria, macro-albuminuria, or end-stage
renal disease.
Cardiovascular co-morbidity: hypertension or ischemic heart disease.
Ophthalmic co-morbidity: simple or proliferative diabetic retinopathy, cataract.
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constitute the majority of the patients.
The high percentage (28.8%) of positive family history
of DM in our patients underlines the important role of
genetics in this condition. Mean duration of DFU was
79.8 days, which means that there was a two-month gap
between DFU development and referral. Early treatment
of DFU is an important factor in achieving better thera-
peutic results; consequently, it is vitally important that
patients and primary care physicians be sufficiently
educated and the former be encouraged to seek treat-
ment earlier.
While in some patients (3 cases) DM was firstly
presented with DFU, mean duration of DM in our pa-
tients was 172.2 months (14.3 years). In other similar
studies in Iran, mean duration of DM was also about 14
to 15 years [23,26]. A study from Singapore [24]
reported that duration of DM in 58.4% of the patients
was more than 10 years. Only 4.18% of our patients had
DM durations of 12 months or less which suggests that
although DFU can develop in a diabetic patient at any
time, it could be deemed a long-term complication of
DM in most cases.Table 4 Locations of DFU (% of the patients)
Location of DFU Percentage
Toe 44.5




Site of previous surgery 2.9
Malleoles 2.7
Between toes 1.9
Lateral or medial aspects of foot 1.3
Ankle 1
More than one location 11.3
DFU: Diabetic foot ulcer.91.75% of our patients were under treatment to decrease
their blood sugar; be that as it may, most of the cases
(85.6%) had poor DM control (as indicated by their
HbA1C levels > 7%) and 69.6% of the cases had preceding
episodes of hospitalization due to DM co-morbidities.
Chiming in with previous reports, these findings suggest
that DFU is most likely to develop in diabetic patients
with poor control of blood sugar [24,26,28,29]. Based on
the fact that more than 50% of the patients had cardiovas-
cular and renal and more than 40% had ophthalmic co-
morbidities, we think that conducting a complete review
of systems in DFU patients with emphasis on these
systems is inevitable. Prevalence of sensorimotor and es-
pecially autonomic neuropathy was lower than similar
studies. Considering the fact that diagnosis of autonomic
neuropathy is based on history taking, the low prevalence
of autonomic neuropathy could be in part due to incom-
plete history taking in some cases.
Several studies have conclusively shown that DFU is
more common in patients with previous history of foot
ulceration or amputation [30,31]. Apelqvist and col-
leagues found a DFU amputation recurrence rate of 34%
after 1 year and 70% after 5 years [32]. Risk of DFU
development in patients with history of previous ulcer is
57 times more than that of patients without this history
[33]. Of our cases, 22.4% had history of previous
hospitalization because of DFU and 16.3% had preceding
lower-limb amputations. Therefore, recurrence of DFU
is a major point of concern in DM patients, which
underscores the importance of DFU prevention in DM
patients and appropriate patient education to prevent
secondary ulcers. Additionally, 47.2% of the cases had
history of previous hospitalizations due to other co-
morbidities of DM, including cardiovascular, cerebrovas-
cular, renal, and ophthalmic complications. Furthermore,
even a larger number of our patients had these co-
morbidities based on evaluations made during their
admission. Reports about the relationship between these
co-morbidities and DFU development are controversial
but many reports have concluded that presence of every sin-
gle one of these co-morbidities is an independent risk factor
for development of DFU and amputation [26,29,30,32].
We also found that most DFU cases were of the ische-
mic (74.1%) followed by the neuropathic type. Shojaiefard
and colleagues [26] reported the same results and along
with Nather and colleagues [24] concluded that presence
of ischemic ulcer and gangrene was a risk factor for ampu-
tation. The ratio of right limb DFU to left limb DFU was
1:1.37. It seems that it is because most of the patients are
right-dominant and use their right limb more frequently
which might expose the right lower limb to more frequent
traumas.
The most prevalent locations involved were toes (big
toe followed by the second toe), plantar aspect of the
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than 70% of the cases. Other investigators have reported
similar results [25]. It seems that risk of DFU develop-
ment in more distal parts of the limbs, which are prone
to ischemia, diabetic neuropathy, and traumas, is much
more than that of the proximal parts. Moreover, 26 pa-
tients developed DFU at the site of previous surgeries
like amputation, debridement, or venous graft removal
for CABG. Physicians should remember this point and
avoid unnecessary surgical manipulations in lower limbs
of DM patients.
Our patients were hospitalized for an average of
16.7 days; and at the end, 28.2% needed amputations.
The minor-to-major amputation ratio was 1:1.61. The
rate of amputation varies in different reports from dif-
ferent countries. The global rate is reported to be about
14–24% of the patients [34,35] and 15% in western
countries [36]. The rate was 27.2% in a study in
Singapore in 2008 [22] and 28.5% in Sudan in 2005 [25].
In Iran also there are different reports ranging from
40% in 1995 and 20% in 1999 [23] to 28.1% in 2005 [26].
An interesting result was the point that the amputation
rate in one hospital was lower than that in the other
(23.7% vs. 30.1%). At the hospital with the lower rate of
amputation, since the year 2000 a “multidisciplinary ap-
proach “ has been adhered to for prevention and early case
detection through patient and personnel education and
multiple therapies (frequent debridement, drainage, wash-
ing, and dressing along with antibiotic therapy and daily
assessment of the healing process) managed by a team of
orthopedic surgeon, vascular surgeon, infectious diseases
specialist, internist, endocrinologist, interventional cardi-
ologist, nurse, general practitioner, and physiotherapist
[23,26]. It is likely that application of this approach re-
duced the rate of amputation in DFU patients of this
hospital. There are other reports about decreased rates of
amputation thanks to this approach [23,37,38].
Conclusions
Long duration of hospitalization of our patients in tandem
with high percentage of the amputations and overall mor-
tality rates highlights the high burden of DFU and the sig-
nificance of its prevention and early treatment. Besides,
number of our DFU patients is increasing which denotes
the need for allocating more resources.
The status of DM care in our patients is far from satis-
factory. Moreover, regarding the fact that DFU is most
likely to develop in patients with poor DM control, it is in-
evitable that patient education should be afforded its due
attention. In addition, while cardiovascular, renal and
ophthalmic co-morbidities are common in DFU patients,
it is important to conduct a complete review of systems
(and not only approach to DFU) in DFU patients with em-
phasis on these systems. Primary care physicians shouldbe furnished with the information presented in the present
study. To conclude, a multidisciplinary approach can con-
fer better treatment and outcome with respect to DFU.
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